The Pharmaceutical and Healthcare Association of the Philippines (PHAP) recently vowed to continue to treat “national development priorities as business priorities” following the newly released study authored by the Singapore–based IMS consulting Group (IMSCG) showing that Philippine pharmaceutical industry is seen as the key players in national development.
“We in the pharmaceutical sector have always placed CSR [corporate social responsibility] at the heart of what we do… we believe that we have a bigger role in building a health system that serves every Filipino,” PHAP Executive Director Teodoro B. Padilla said during the Global Forum on Research and Innovation for Health 2015 held at the Philippine International Convention Center in Pasay City.
The study titled: “The Contributions of the Philippine Pharmaceutical Industry to Health and Economy,” which was launched during the Forum 2015, stated that the Philippine pharmaceutical industry has been a bastion of CSR over the past 12 years, partnering with doctors, patient associations, communities, the government, non-governmental organizations (NGOs) and other stakeholder groups in elevating health care in the Philippines.
Likewise, the IMSCG study finds that important advances have been made by the Philippine pharmaceutical industry in saving patients’ lives; building strong partnerships with relevant groups; and driving economic growth.